JNJ 17029259

JNJ 17029259 is an orally active and selective VEGF-R2 kinase inhibitor. JNJ 17029259 inhibits VEGF-mediated signal transduction. JNJ 17029259 has anti-angiogenic activity[1][2].

Product Specifications

CAS Number

[314267-57-7]

UNSPSC

12352005

Target

VEGFR

Type

Reference compound

Related Pathways

Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/jnj-17029259.html

Solubility

10 mM in DMSO

Smiles

CC(C)(N)C(C=C1)=CC=C1C2=NC(NC3=CC=C(CCN4CCOCC4)C=C3)=NC=C2C#N

Molecular Formula

C26H30N6O

Molecular Weight

442.56

References & Citations

[1]Mohammed S. I. Makki, et al. Fluorine Substituted 1,2,4-Triazinones as Potential Anti-HIV-1 and CDK2 Inhibitors. Journal of Chemistry. 2014. Article ID 430573.|[2]Reuman M, et al. Scalable synthesis of the VEGF-R2 kinase inhibitor JNJ-17029259 using ultrasound-mediated addition of MeLi-CeCl3 to a nitrile. J Org Chem. 2008 Feb 1;73 (3) :1121-3.